Human brain aldolase C4 isoenzyme: purification, radioimmunoassay, and distribution in human tissues

New astroglial injury-defined biomarkers for neurotrauma assessment

Traumatic brain injury (TBI) is an expanding public health epidemic with pathophysiology that is difficult to diagnose and thus treat. TBI biomarkers should assess patients across severities and reveal pathophysiology, but currently, their kinetics and specificity are unclear. No single ideal TBI biomarker exists. We identified new candidates from a TBI CSF proteome by selecting trauma-released, astrocyte-enriched proteins including aldolase C (ALDOC), its 38kD breakdown product (BDP), brain lipid binding protein (BLBP), astrocytic phosphoprotein (PEA15), glutamine synthetase (GS) and new 18-25kD-GFAP-BDPs. Their levels increased over four orders of magnitude in severe TBI CSF. First post-injury week, ALDOC levels were markedly high and stable. Short-lived BLBP and PEA15 related to injury progression. ALDOC, BLBP and PEA15 appeared hyper-acutely and were similarly robust in severe and mild TBI blood; 25kD-GFAP-BDP appeared overnight after TBI and was rarely present after mild TBI. Using a human culture trauma model, we investigated biomarker kinetics. Wounded (mechanoporated) astrocytes released ALDOC, BLBP and PEA15 acutely. Delayed cell death corresponded with GFAP release and proteolysis into small GFAP-BDPs. Associating biomarkers with cellular injury stages produced astroglial injury-defined (AID) biomarkers that facilitate TBI assessment, as neurological deficits are rooted not only in death of CNS cells, but also in their functional compromise.

A novel anti-aldolase C antibody specifically interacts with residues 85-102 of the protein

Aldolase C is a brain-specific glycolytic isozyme whose complete repertoire of functions are obscure. This lack of knowledge can be addressed using molecular tools that discriminate the protein from the homologous, ubiquitous paralog aldolase A. The anti-aldolase C antibodies currently available are polyclonal and not highly specific. We obtained the novel monoclonal antibody 9F against human aldolase C, characterized its isoform specificity and tested its performance. First, we investigated the specificity of 9F for aldolase C. Then, using bioinformatic tools coupled to molecular cloning and chemical synthesis approaches, we produced truncated human aldolase C fragments, and assessed 9F binding to these fragments by western blot and ELISA assays. This strategy revealed that residues 85–102 harbor the epitope-containing region recognized by 9F. The efficiency of 9F was demonstrated also for immunoprecipitation assays. Finally, surface plasmon resonance revealed that the protein has a high affinity toward the epitope-containing peptide. Taken together, our findings show that epitope recognition is sequence-driven and is independent of the three-dimensional structure. In conclusion, given its specific molecular interaction, 9F is a novel and powerful tool to investigate aldolase C’s functions in the brain.

A new soluble brain-specific protein: identification and partial purification

A new soluble 170-kDa protein (BP170) was found to be present exclusively in the brain of all the vertebrates that we studied by Western immunoblotting. It was not detected in peripheral rat tissues, including heart, kidney, liver, spleen, lung, muscle, adrenal, intestinal mucosa, sciatic nerve, or pituitary. In rat brain, its regional distribution was found to be heterogeneous, with its highest concentration in the cerebrum and its lowest in the hypothalamus, and 89% of it was in the post-microsomal fraction. BP170 constitutes at least 0.05% of the total brain cytosol proteins. Its level increases during development, being the lowest at 5 days and the highest at 90 days postnatal. BP170 is a single-chain polypeptide. It could be partially purified by precipitation with polyethylene glycol followed by column chromatography on Q Sepharose. Although BP170 was identified by an antiserum against puromycin-sensitive aminopeptidase (PSA), the two proteins differ in molecular weight, chromatographic properties, regional and subcellular distribution, developmental changes, immunoreactivity, and enzyme activity. Self-incubation or trypsin treatment of the partially purified BP170 generates no PSA activity, indicating that BP170 is not a PSA precursor. Furthermore, BP170 is neither an inhibitor nor an activator of PSA. Our data suggest that BP170 is a novel brain-specific protein not previously described.

Characterization of the transcription-initiation site and of the promoter region within the 5' flanking region of the human aldolase C gene

Several aldolase C clones from a human genomic library have been identified using a mouse aldolase C cDNA as a hybridization probe. The most complete fragment of the clones identified is 14 kb long and contains the complete aldolase C gene. The nucleotide sequence analysis of more than 5 kb includes the intron/exon organization structure of the gene and the 3' and 5' flanking regions. Although no human cDNA is yet available, a canonical polyadenylation signal at the 3' end of the gene indicates the proximity of the poly(A) addition site. We have analyzed the 5' noncoding region by S1 mapping and primer-extension experiments. The transcription-initiation sites for the human aldolase C gene in brain tissue was located about 1300 bp upstream from the methionine initiation codon. Preliminary functional assays of the promoter by transfection into rat glioma cells have indicated that promoter elements lie between positions -161 and -416 from the start point of transcription.

Sensitive enzyme immunoassay for human aldolase B

A highly sensitive enzyme immunoassay system for measurement of aldolase B subunit (aldolase B) was established. Antisera were raised in rabbits by injecting aldolase B4 purified from human liver, and specific antibodies to aldolase B were purified by the use of a column of aldolase B4-coupled Sepharose. The purified antibody IgG was digested with pepsin to obtain the F(ab)' fragments. The antibody F(ab)' fragments were immobilized noncovalently on polystyrene balls, and the same antibody Fab' fragments were labeled with beta-D-galactosidase from Escherichia coli. The sandwich-type assay system using these reagents was sensitive and specific to aldolase B, showing no cross-reactivity with aldolase-A or aldolase-C. The minimum detection limit of the assay was 3 pg aldolase B4/assay tube. The immunoreactive aldolase B was present at high levels in the liver and kidney, and considerably in the small intestine. It was detected in all the tissues examined. Immunohistochemically, aldolase B is localized in hepatocytes, proximal renal tubular cells and epithelial cells of small intestine. Serum levels of aldolase B in healthy subjects were ranged from 33 to 202 ng/ml.

Monoclonal antibody to aldolase C: a selective marker for Purkinje cells in the human cerebellum

A monoclonal antibody to the glycolytic enzyme aldolase C was used in an immunoperoxidase technique on unfixed and formalin-fixed paraffin-embedded tissues from the human central nervous system (CNS) and other tissues. No staining outside the CNS was detected. In the central nervous system the antibody gave a selective and intense staining of Purkinje cell perikarya, axons and dendrites in both fixed and unfixed tissues. In the human fetal brain, positive staining of Purkinje cells was seen from 35-36 weeks' gestation onwards. This coincides with the conversion of Purkinje cells to a tetraploid state, and may reflect increased glycolytic activity accompanying the rapid dendritic growth at this stage of development. Preliminary investigations on a variety of disease states suggest that this antibody may be useful in studies of ischaemic damage, congenital abnormalities and degenerative conditions affecting the cerebellum.

Brain metabolic correlates of hypoxic-ischemic cerebral necrosis in mid-gestational sheep fetuses: significance of hypotension

Mid-gestational sheep fetuses exposed to marked hypoxia for 2 h remain brain intact if MABP is maintained above 30 mm Hg. On the other hand, similarly hypoxic fetuses, if they experience reductions in MABP below 30 mm Hg, develop foci of necrosis that predominantly affect hemispheric white matter and neostriatum. Cortex damage is more restricted and is usually associated with more massive underlying white matter damage. The present study examines the brain metabolic basis for the important role of hypotension in brain injury development in marked hypoxia. Sheep fetuses rendered hypoxic by respiring their ewes with 11% oxygen (fetal PaO2 = 8-12 mm Hg) in which MABP was maintained above 30 mm Hg showed increases in brain lactic acid concentrations to 7-13 mumol/g but unaltered energy charge. In contrast, fetuses that sustained MABP reductions below 30 mm Hg showed increases in lactic acid concentrations in vulnerable structures to 16-24 mumol/g accompanied by marked decreases in energy charge. The vulnerable structures also showed reductions in fructose concentrations but a variable behavior of other brain metabolites including phosphocreatine, glycogen, and glucose. Thus, the present findings suggest a relation between hypotension during marked hypoxia, low energy charge, lactic acid accumulation in brain at high concentrations, and fetal brain injury. The ewes of hypoxic hypotensive fetuses received pentobarbital at lower doses than did those of fetuses that maintained blood pressure. This suggests that pentobarbital plays an important role in protecting the fetal brain from asphyxia by extending the hypoxic fetus's ability to maintain blood pressure in addition to reducing its brain metabolism.

Structure and expression of mouse aldolase genes. Brain-specific aldolase C amino acid sequence is closely related to aldolase A

Brain-specific aldolase C amino acid sequence (greater than 75% of the coding region) was determined for the first time. Two cDNA clones, pAM1 and pAM2, were identified, from a mouse brain library, by using human aldolase B cDNA as a probe. The larger one, pAM2, identified as a cDNA for aldolase C, has been completely sequenced and covers the 5'-untranslated region of the mRNA and the codons for amino acids 1-227 of the protein. The sequence indicates that aldolase C is more akin to aldolase A than to aldolase B. A cDNA library from mouse muscle was also screened, allowing the identification of clones pAM3 and pAM4, which contain cDNAs for aldolase A. The sequence obtained from pAM3 covers 70% of the coding sequence (amino acids 99-355) from the -COOH part of the protein. The cDNAs for the three aldolases, A, B and C, have been hybridized to RNA from various rat tissues. The results confirm the tissue specificity of the expression of the mRNA for the different isoenzymes and support the hypothesis that aldolase C expression, as aldolase A and B, is regulated at the transcriptional level or, in any case, via mRNA concentration.

Highly sensitive enzyme immunoassay for human brain aldolase C

A sensitive sandwich-type enzyme immunoassay for brain-type isozyme of human aldolase C4 was developed using purified antibodies specific to the C subunit. The antibodies were raised in rabbits by injecting the purified aldolase C4, and purified by means of immunoaffinity chromatography on a column of aldolase C4-coupled Sepharose. The assay system consisted of polystyrene balls with immobilized antibody F(ab')2 fragments and the same antibody Fab' fragments labelled with beta-D-galactosidase from Escherichia coli. The assay was highly sensitive and the minimum detection limit of aldolase C4 was 3 pg/tube. The assay was specific to the C subunit of aldolase (aldolase C). It cross-reacted about 60% with aldolase AC3, 30% with aldolase A2C2, and 4% with aldolase A3C, but showed no cross-reactivity with aldolase A4, the muscle-type isozyme. Coefficients of variation in within-run and between-run precision studies for serum aldolase C were less than or equal to 11%. Serum aldolase C levels in healthy adults of various ages (16-59 yr old) and both sexes ranged from 8.74-18.9 ng/ml. Immunoreactive aldolase C in the extracts of various human tissues was determined. It was distributed at high concentrations in the central nervous tissue and heart and at significant levels in liver, adrenal glands and testis. The assay of aldolase C in cerebrospinal fluid or serum by employing this sensitive immunoassay might be useful in the diagnosis of neurological disorders or acute myocardial damage.

Levels of immunoreactive aldolase C, creatine kinase-BB, neuronal and non-neuronal enolase, and 14-3-3 protein in circulating human blood cells

Five proteins found in the human nervous system have been measured by radioimmunoassay in human red cells, platelets, and lymphocytes. Two neuronal proteins (neurone-specific enolase and 14-3-3 protein) occur in platelets at levels equivalent to their concentration in brain, and in erythrocytes at levels approximately 10% of the level in brain. Two proteins characteristic of astrocytes in the cerebral cortex (creatine kinase BB and aldolase C) occur at low levels in platelets and are virtually undetectable in erythrocytes and lymphocytes. The more widely distributed non-neuronal enolase is present in erythrocytes, platelets and lymphocytes. The neurone-specific enolase and 14-3-3 protein immunoreactivities found in circulating blood cells have been characterised in terms of molecular mass, charge, and dilution characteristics in the respective radioimmunoassay and in each case appears to represent the intact protein. Controlled lysis of erythrocytes releases neurone-specific enolase and 14-3-3 protein in parallel with haemoglobin. The occurrence of brain proteins in circulating blood cells (which appears to be a species-dependent phenomenon) has the practical clinical consequence that minor degrees of especially red cell lysis can produce high serum levels of immunoreactivity. This represents a pitfall in the measurement of these proteins in serum as tumour markers or as indices of damage to the central nervous system.

Isolation of PGP 9.5, a new human neurone-specific protein detected by high-resolution two-dimensional electrophoresis

Protein gene product (PGP) 9.5 is a new brain-specific protein originally detected by high-resolution two-dimensional electrophoresis of the soluble proteins of human brain and other organs. We have purified this protein from human brain and raised a rabbit antihuman PGP 9.5 antiserum. The protein has a monomer molecular weight of approximately 27,000 and is present in brain at concentrations at least 50 times greater than in other organs. Immunoperoxidase labelling has localised PGP 9.5 to neurones in the human cerebral cortex with no evidence of staining of glial elements. PGP 9.5 is estimated to be present in brain at concentrations of 200-500 micrograms/g wet weight and represents a major protein component of neuronal cytoplasm. This new neurone-specific cytoplasmic marker may prove useful in studies of neuronal development and in the detection of neuronal damage in disease of the nervous system.

Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders

An antiserum to human 14-3-3 protein has been produced in rabbits. The protein was a poor antigen and attempts to improve immunogenicity were unsuccessful. A radioimmunoassay was developed using the antiserum, 125I-14-3-3-2, and unlabelled 14-3-3-2 as standards. The assay had a sensitivity limit of 2.5 ng.ml-1. The minor component of human 14-3-3 protein (14-3-3-1 protein) cross-reacted to approximately 10% in the assay. Human tissues were surveyed for 14-3- protein by two-dimensional electrophoresis and by radioimmunoassay. Two-dimensional electrophoresis showed a 14-3-3 protein complex in brain, intestine, and testis, but not in other tissues. Radioimmunoassay showed that although brain had the highest concentration of 14-3-3 (13.3 microgram.mg-1 soluble protein), immunoreactivity was present in all tissues, with the concentration in intestine and testis approaching 50% of the brain level. Lower levels (less than 1.0 microgram.mg-1 soluble protein) were seen in liver, kidney, skeletal muscle, and erythrocytes. The immunoreactivity present in tissues other than brain showed the same molecular weight and charge characteristics and authentic 14-3-3 protein. The radioimmunoassay also detected 14-3-3 protein in serum (50 ng.ml-1) and in CSF (5-130 ng.ml). The immunoreactivity present in CSF appeared to be intact 14-3-3 protein. CSF 14-3-3 levels were measured in 82 patients with various neurological disorders. Measurements of this protein did not appear sufficiently discriminating to be of diagnostic value.

Purification, properties, and immunohistochemical localisation of human brain 14-3-3 protein

A protein has been purified from human brain that appears to be the human equivalent of bovine 14-3-3 protein. On polyacrylamide gel electrophoresis the protein migrates as a faster major component, termed 14-3-3-2 protein, and a slower minor component, termed 14-3-3-1 protein, which consists of approximately 12% of the total protein. Both 14-3-3-1 and 14-3-3-2 have a native molecular weight of approximately 67,000. 14-3-3-2 appears to have the subunit composition alpha beta; 14-3-3-1 has the composition beta'beta'. Peptide mapping with Staphylococcus aureus V8 proteinase shows that alpha and beta subunits are unrelated but the beta and beta' subunits show some common peptides. Immunoperoxidase labelling shows that 14-3-3 is localised in neurones in the human cerebral cortex. 14-3-3 shows no enolase, creatine kinase, triose phosphate isomerase, ATPase, cyclic nucleotide-dependent protein kinase, or purine nucleoside phosphorylase activity. 14-3-3 does not bind calcium and does not appear to be related to calmodulin, calcineurin, tubulin, neurofilament proteins, clathrin-associated proteins, or tropomyosin. The functional significance of this neuronal protein remains obscure.

Cellular localization of aldolase C subunits in human brain

An antiserum specific for the brain-type aldolase C subunit has been used to investigate the cellular localization of this protein in human brain. Immunoperoxidase labeling at the light microscope level showed heavy staining of Purkinje cells in the cerebellum and of astrocytes in the cerebrum. Faint staining of occasional large neurons in the gray matter of the cerebral cortex was also seen.

Radioimmunoassay for human aldolase A

A radioimmunoassay was developed for the direct quantification of aldolase A in human serum. The method is a double antibody radioimmunoassay using radioiodinated aldolase A4 homopolymer as ligand, chicken antibodies to aldolase A, and rabbit antibodies to chicken IgG. The lowest measurable amount by this method was 2 ng (0.01 U). The radioimmunoassay was shown to be specific for the aldolase A subunit, with no cross-reactivity with human aldolase B subunits or homopolymeric human aldolase C (C4). The immunoreactive aldolase A in the sera of 41 normal healthy subjects ranged from 130 to 210 ng/ml (0.81-1.31 U/1), with a mean of 171 /+- 39 ng/ml.

The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis

High-resolution multiple two-dimensional polyacrylamide gel electrophoresis (ISODALT) has been used to analyse soluble protein extracts from human brain and 12 other human organs. Approximately 200 protein gene products can be visualised on an electrophoretogram of soluble human brain proteins. By electrophoresing extracts of different human organs separately and mixed with brain extract, 8 proteins have been found which appear to be present in brain in concentrations at least 20 times greater than in any other organ. Four of these brain-specific proteins have been identified by co-electrophoresis with purified proteins as 14-3-2 protein, creatine kinase-BB isoenzyme, aldolase C4 isoenzyme, and 14-3-3 protein. The identities of the remaining 4 proteins are unknown.